medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2021, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2021; 38 (2)

Measles

Martínez-Medina MÁ, Cano-Rangel MA, Palacios-Castro RA, Canales-Guerrero CJ, Hurtado-Valenzuela JG

Language: Spanish
References: 44
Page: 102-117
PDF size: 352.27 Kb.


ABSTRACT

Measles virus is one of the most highly contagious human pathogens known. A typical case of measles is easily recognized during outbreaks, the clinical diagnosis is challenging to many clinicians who have not seen measles in patients. A generalized maculopapular rash, fever and cough, coryza, or conjunctivitis has a high sensitivity. The most common laboratory method for confirming measles is detection of measles virus–specific IgM antibodies in a blood specimen. Measles has historically been a serious disease in malnourished Mexican children, and was recognized as one of the main causes of infant morbidity and mortality. Two doses of measles-containing vaccine is the standard of care for the prevention of measles.


REFERENCES

  1. Orenstein WA. The role of measles elimination in development of a national immunization program. PIDJ. 2006; 25(12): 1093-101.

  2. Dabbagh A, Laws RL, Steulet C, et al. Progress toward regional measles elimination-Worldwide, 2000– 2017. MMWR Morb Mortal Wkly Rep. 2018; 67: 1323-9.

  3. Strebel PM, Orenstein WA. Measles. N Engl J Med. 2019; 381; 4: 349-57.

  4. Sosa, M. J. et al. Epidemiología de las complicaciones del sarampión observadas en el Hospital Infantil de México. Bol Med Hosp Infant Mex.1963; 20(2): 305-15.

  5. Ávila FC, Navarrete NS, Martínez AM, Ruiz GE, Santos JI. Complicaciones en niños con sarampión. Bol Med Hospt Infant Mex. 1990; 47(7): 520-23.

  6. Carrada, T, Velázquez G. El Impacto del sarampión en México. Salud Pub Mex. 1980; 359-408.

  7. Santos JI, Nakamura MA, Godoy MV, Kuri P, Lucas CA, Conyer RT. Measles in Mexico, 1941-2001: Interruption of endemic transmission and lessons learned. JID. 2004; 189(Suppl 1): S243-50.

  8. Verduzco E, Calderón, C, Velázquez FE. Repercusiones de la vacunación contra el sarampión. Salud Pub Mex. 1974; 16: 707.

  9. Velásquez-Monroy OJ, Álvarez-Lucas CH, Lezana- Fernández MA, Ávila-Figueroa C. Panorama epidemiológico del sarampión en México: situación actual y perspectivas. Bol Med Hosp Infant Mex. 1990; 47: 462-73.

  10. Fernández-De Castro J, Kumate J. Sarampión: la vacunación contra el sarampión. Situación en México y en América Latina. Bol Med Hosp Infant Mex. 1990; 47: 449-61.

  11. Cárdenas-Ayala VM, Sánchez-Vargas C. El impacto social de la vacunación contra el sarampión en México. Comentarios durante el curso de la epidemia de 1989-1990. Bol Med Hosp Infant Mex. 1990; 47: 500-5.

  12. Santos Preciado JI, Veras-Godoy ME, Flores-del Campo G. Indicadores de atención a la salud del niño. Gac Med Mex. 2000; 136(suppl): S11-20.

  13. Moss WJ. Lancet. 2017 (Dec 2); 390(10111): 2490- 2502.

  14. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009; 9: 291-300.

  15. Sartwell PE. The incubation period and the dynamics of infectious disease. Am J Epidemiol. 1966; 83: 204-06.

  16. Moss WJ, Strebel P. Biological feasibility of measles eradication. J Infect Dis. 2011; 204: S47-53.

  17. Secretaría de Salud. Subsecretaría de Prevención y Promoción de la Salud Dirección General de Epidemiología. Boletín Informativo. 2020; 19(de Cierre del Brote de Sarampión).

  18. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med. 1954; 86: 277-286.

  19. Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol. 2006; 4: 900-908.

  20. Ludlow M, McQuaid S, Milner D, de Swart RL, Duprex WP. Pathological consequences of systemic measles virus infection. J Pathol. 2015; 235: 253-65.

  21. Nakatsu Y, Takeda M, Ohno S, Shirogane Y, Iwasaki M, Yanagi Y. Measles virus circumvents the host interferon response by different actions of the C and V proteins. J Virol. 2008; 82: 8296-306.

  22. Young MK, Nimmo GR, Cripps AW, Jones MA. Post-exposure passive immunization for preventing measles. Cochrane Database Syst Rev. 2014: 4: Cd010056.

  23. Moss WJ, Ryon JJ, Monze M, Griffin DE. Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J Infect Dis. 2002; 186: 879-87.

  24. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015; 348: 694-99.

  25. Clinica, G. Diagnostico Diferencial de los Exantemas Infecciosos en la Infancia. [En línea]. http://www. cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/ 588_GPC_Exantemasinfecciososenlainfancia/ 588GER.pdf

  26. Luis-Delpiano LA. Sarampion: la enfermedad, epidemiologia, historia y los programas de vacunacion en Chile. Infectologia al Dia. 2015; 1-13.

  27. Kumate J, Gutierrez G, Muñoz O, Santos I, Solorzano F, Miranda G. Infectologia Clinica Kumate-Gu tierrez (Decimoseptima ed.). 2013; Ciudad Mexico: Méndez Editores.

  28. Cherry J, Zahn M. Clinical characteristics of measles in previously vaccinated and unvaccinated patients in California. CID. 2018; 1-5.

  29. Husada D, Kusdwijono, Puspitasari D, Kartina L, Basuki PS, Ismoedijanto. An evaluation of the clinical features of measles virus infection for diagnosis in children within a limited resources setting. BMC Ped. 2020; 20(5): 3-10.

  30. Strebel PM, Orenstein WA. Measles. N Engl J Med. 2019; 381; 4: 2019:349-357.

  31. McLean H, Orenstein. Protecting Young Infants From Measles. Pediatrics. 2019. 144(6): e2019254.

  32. Gans H, Maldonado YA. Measles: Clinical manifestations, diagnosis, treatment, and prevention. En: Hirsch MS, Kaplan SL, Sullivan M, eds. UpToDate. [internet]. Waltham (MA): UpToDate Inc; 2018. En línea, r:. Disponible en: https://www.uptodate.com/ contents/measles-clinical-manifestations-diagnosis- treatment-and-prevention.

  33. Analucia RX, Thalles Rodrigues, Lucas Santos, Gilmar Lacerda. Clinical laboratorial diagnosis and prophylaxis of measles in Brazil. J Bras Patol Med Lab. 2019; 55(4): 390-95.

  34. Liersch J, Omaj R, Schaller J. Histopathological and immunohistochemical characteristics of measles exanthema: A study of a series of 13 adult cases and review of the literature. Am J Dermatopathol. 2019; 41(12): 914-23.

  35. Lo Vecchio A, Krzysztofiak A, Montagnani C for the SITIP Measles Study Group, et al. Complications and risk factors for severe outcome in children with measles. Arch Dis Child. 2020;105(9): 896-899.

  36. Sánchez-Rebolledo JM, Gutiérrez G, et al. Sarampión. Análisis clínico y epidemiológico de 788 casos complicados. Rev Mex Pediatr. 1967; 34: 65-72.

  37. Kaune Criales V. Exantemas frecuentes en Pediatria. Rev Soc Bol Ped. 2013; 52(2): 125-31.

  38. Husada Kusdwijiono D, Puspitasari D, Kartina L. An evaluation of the clinical features of measles virus infection for diagnosis in children within a limited resources setting. BMC Ped. 2020; 20(5); 3-10.

  39. American Academy of Pediatrics. Measles. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. Itasca, IL: American Academy of Pediatrics. 2021: 503-19.

  40. Bichon A, Aubry C, Benarous L, Drouet H, Zandotti C, Parola P, et al. Case report: Ribavirin and vitamin A in a severe case of measles. Medicine (Baltimore). 2017 Dec; 96(50): e9154. [En línea 2017, 15 Dic.].

  41. Herrera-Benavente IF, Comas-García A, Romero-Feregrino R, Romero-Feregrino R, Ochoa-Pérez UR, Madrigal Alonso B, et al. Consenso de sarampión: recomendaciones basadas en evidencia para la vacunación 2019. Rev Latin Infect Pediatr. 2019; 32(4): 157-167.

  42. Durrheim MB. Measles elimination. N Engl J Med. 2016; 375(14); 1392-93.

  43. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid- nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998; 351: 637-41.

  44. Secretaría de Salud. Dirección General de Epidemiología. Manual de Procedimientos Estandarizados para la Vigilancia Epidemiológica de las Enfermedades Prevenibles por Vacunación. Vigilancia Epidemiológica de Enfermedad Febril Exantemática, 19-39.




2020     |     www.medigraphic.com